熱門資訊> 正文
Jazz Pharma Epidyolex三期试验在日本失败
2024-08-23 05:03
- 爵士製藥(JAZZ) 0
- 雷諾士(LII) 0
- A phase 3 trial of Jazz Pharmaceuticals' (NASDAQ:JAZZ) Epidyolex (cannabidiol) failed in a Japanese study examining the drug to treat seizures associated with several conditions in pediatric patients.
- The primary efficacy endpoint was a pre-specified percentage change in indication-associated seizure frequency during the treatment period of up to 16 weeks.
- The company noted that Epidyolex's efficacy has been demonstrated in five other phase 3 trials of more than 900 patients.
- Jazz said it would discuss with Japanese regulators about a potential new drug application for Epidyolex.
- Epidyolex is approved in the U.S. and EU (known as Epidiolex in the U.S.) for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex.
More on Jazz Pharmaceuticals
- Jazz Pharmaceuticals plc 2024 Q2 - Results - Earnings Call Presentation
- Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
- Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
- Jazz Pharmaceuticals beats Q2 estimates, narrows FY revenue guidance
- Jazz Pharmaceuticals Q2 2024 Earnings Preview
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
